Compare FSLY & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | CRNX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 2019 | 2018 |
| Metric | FSLY | CRNX |
|---|---|---|
| Price | $33.99 | $39.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $15.67 | ★ $76.63 |
| AVG Volume (30 Days) | ★ 10.6M | 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,018,000.00 | $1,039,000.00 |
| Revenue This Year | $16.43 | $720.10 |
| Revenue Next Year | $10.45 | $184.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.78 | N/A |
| 52 Week Low | $5.13 | $25.48 |
| 52 Week High | $34.22 | $57.99 |
| Indicator | FSLY | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 69.83 | 57.82 |
| Support Level | $8.03 | $39.35 |
| Resistance Level | N/A | $45.32 |
| Average True Range (ATR) | 2.69 | 1.64 |
| MACD | 0.20 | 0.83 |
| Stochastic Oscillator | 92.95 | 94.39 |
Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.